LL-37: Research & Studies

Research Overview#

The research literature on LL-37 spans hundreds of preclinical studies across multiple therapeutic areas. Below is a structured review of the key studies, systematic reviews, and identified research gaps.

Key Preclinical Studies#

Most important and highly cited LL-37 studies (designs, sample sizes, key findings, and PubMed IDs)

• Bals 1998 (PNAS): Human lung expression and airway antimicrobial activity • Design: Expression/localization in human lung epithelium (in situ hybridization, RNA), peptide isolation from airway surface fluid/xenograft; in vitro bactericidal assays with synthetic LL-37. • Sample size (N): Not specified in the retrieved excerpt. • Population/model: Human airway epithelial tissue, airway surface fluid, human bronchial xenograft model. • Key findings: LL-37/hCAP-18 is produced by airway epithelial cells, secreted onto the airway surface, and displays broad antimicrobial activity that is salt-sensitive and synergizes with lactoferrin/lysozyme, supporting a role in innate pulmonary defense (bactericidal data shown across Gram-negative and Gram-positive bacteria). • PubMed ID: Not specified in the retrieved excerpt.

• Turner 1998 (Antimicrobial Agents and Chemotherapy): Broad antimicrobial and mechanistic characterization • Design: In vitro profiling using radial diffusion and broth microdilution against diverse bacteria/fungi; membrane permeabilization assays; LPS binding; circular dichroism. • N: Not applicable for human subjects; organism panels and biophysical assays were used. • Population/model: Synthetic LL-37 tested against P. aeruginosa, S. typhimurium, E. coli, L. monocytogenes, Staphylococci, VRE, MRSA, Proteus, Candida, and model membranes/LPS. • Key findings: LL-37 exhibited broad-spectrum antimicrobial activity, permeabilized bacterial membranes, bound E. coli LPS with high affinity/positive cooperativity, and adopted an α-helical conformation in lipid environments; some activity was salt-sensitive. • PubMed ID: Not specified in the retrieved excerpts.

• Koczulla 2003 (Journal of Clinical Investigation): Angiogenesis and arteriogenesis • Design: Multi-model study—endothelial cell proliferation/tube formation assays, CAM neovascularization, rabbit hind-limb ischemia, and mouse wound-healing with CRAMP (cathelicidin) deficiency; receptor/mechanism studies. • N: Not specified in the retrieved excerpt. • Population/model: HUVECs; CAM; rabbit ischemia model; wild-type vs CRAMP-deficient mice. • Key findings: LL-37 activates endothelial cells (via FPRL1) and promotes angiogenesis/arteriogenesis; CRAMP-deficient mice show decreased wound vascularization, supporting a physiological role in vascularization and repair. • PubMed ID: Not specified in the retrieved excerpt.

• Cirioni 2006 (Antimicrobial Agents and Chemotherapy): Protection in rat sepsis models • Design: Randomized preclinical comparisons in three gram-negative sepsis models (LPS, intraperitoneal live E. coli, and cecal ligation/puncture) versus polymyxin B and conventional antibiotics; outcomes included survival, bacterial loads, endotoxin, and TNF-α. • N: Not specified in the retrieved excerpt. • Population/model: Adult male Wistar rats. • Key findings: LL-37 reduced lethality and bacterial burden, neutralized endotoxin, and lowered TNF-α; activity was comparable to polymyxin B and in some measures superior to conventional antibiotics, highlighting combined antimicrobial and anti-endotoxin properties. • PubMed ID: Not specified in the retrieved excerpts.

• Mily 2013 (BMC Pulmonary Medicine): Phenylbutyrate ± vitamin D3 dose-finding to induce LL-37 • Design: Open, 8-day, dose-finding trial in healthy adults with ex vivo assays of PBMC/MDM after oral phenylbutyrate (PB) ± vitamin D3; LL-37 mRNA/peptide and macrophage intracellular M. tuberculosis killing assessed at days 0, 4, 8. • N: 15 healthy volunteers (retrieved excerpt). • Population/model: Healthy adult volunteers; monocyte-derived macrophages infected ex vivo with M. tuberculosis. • Key findings: PB 500 mg b.i.d. + vitamin D3 5000 IU daily increased LL-37 transcript and peptide in macrophages and enhanced intracellular M. tuberculosis killing; identified a feasible induction regimen for clinical testing. • PubMed ID: Not specified in the retrieved excerpt.

• Miranda 2023 (Archives of Dermatological Research): RCT of LL-37 cream in diabetic foot ulcers • Design: Randomized, double-blind, placebo-controlled trial; twice-weekly topical LL-37 cream vs placebo for 4 weeks; serial digital planimetry and ELISA on wound fluid. • N: Not specified in the retrieved excerpt. • Population/model: Patients with diabetic foot ulcers (mild infection), Jakarta sites. • Key findings: LL-37 cream increased granulation index and accelerated healing metrics at multiple time points versus placebo; IL-1α, TNF-α and aerobic colonization were not significantly reduced overall. • PubMed ID: Not specified in the retrieved excerpt.

Embedded summary table

Notes and limitations

• PubMed IDs (PMIDs) and exact sample sizes were not present in the retrieved excerpts for several studies above. Where missing, we report this explicitly; the DOI, journal, year, and detailed design/findings are documented from the evidence we have.
• Additional seminal LL-37 papers relevant to disease mechanisms and clinical translation (e.g., LL-37–nucleic acid complexes in psoriasis, vitamin D–cathelicidin–autophagy axis, and LL-37 in keratinocyte inflammasome activation) were identified in the search stage, but detailed evidence with PMIDs was not obtained in the excerpts available; hence, they are not included in the main list above to maintain strict alignment with retrievable evidence.
• If you would like, I can perform a focused follow-up to retrieve PMIDs and missing Ns directly from PubMed for the above entries and extend the list with additional landmark studies (e.g., Sørensen 2001 Blood; JEM psoriasis nucleic acid complexes; PLoS Pathog vitamin D–autophagy study).

Systematic Reviews#

Existence and type of reviews/meta-analyses

• Multiple comprehensive narrative reviews on LL-37 exist across immunology, dermatology, oral medicine, and translational therapeutics. These synthesize preclinical and limited clinical data and discuss delivery and safety. No systematic reviews or meta-analyses specifically pooling therapeutic efficacy/safety of LL-37 interventions in humans were identified. One systematic review/meta-analysis addresses vitamin D status and LL-37 levels in tuberculosis as biomarkers, not as an LL-37 therapeutic intervention (biomarker association only).

Efficacy conclusions

• Preclinical: Reviews consistently conclude that LL-37 shows broad antimicrobial, immunomodulatory, wound-healing, and sepsis-protective effects in vitro and in animal models; benefits include modulation of TLR–NFκB signaling, enhancement of NETosis, suppression of macrophage pyroptosis, and promotion of tissue repair.
• Early human signals: A randomized, placebo-controlled phase IIa in venous leg ulcers suggested improved healing at low topical doses, whereas the highest dose lacked benefit and increased local inflammation. A phase IIb trial of a C‑terminal LL-37 derivative (P60.4Ac) as ear drops for chronic suppurative otitis media reduced bacterial load and neutrophil infiltration. Other HDP programs show mixed outcomes; overall clinical efficacy remains limited and indication-specific.
• Exploratory study: A small single-arm COVID-19 study delivering LL-37 via engineered Lactococcus lactis reported symptom improvement signals but is inconclusive for efficacy due to design limitations.

Safety and adverse effects

• Dose-dependent local inflammation was observed at the highest topical LL-37 dose in venous leg ulcers; overall adverse event characterization in trials is limited in the reviews.
• Context-dependent pro- and anti-inflammatory actions are emphasized; LL-37 can induce chemokines and inflammasome activation under certain conditions, and high concentrations can be cytotoxic to host cells.
• Thromboinflammatory/atherogenic risk has emerged as a concern in recent literature linking LL-37 to enhanced LDL uptake and atherosclerosis biology; reviews note thrombosis/thromboinflammation as a safety topic warranting caution.

Translational challenges highlighted by reviews

• Stability and proteolysis: LL-37 is susceptible to degradation and may lose activity in physiological fluids and at physiologic salt/pH; post-translational modifications (e.g., citrullination) alter function.

• Delivery and dosing: Efficacy is sensitive to dose and formulation; nanoparticles, liposomes, and protease-resistant mimetics (e.g., ceragenins) are proposed to improve stability and reduce toxicity.

• Mechanism and context: Benefits may derive from immunomodulation rather than direct microbicidal action; in vivo effects are highly context-dependent, complicating trial design and endpoint selection.

• Yes, there are multiple comprehensive narrative reviews on LL-37; they uniformly report strong preclinical efficacy but only limited, mixed, and indication-specific human efficacy signals to date. Safety concerns include dose-dependent local inflammation, context-dependent proinflammatory effects and cytotoxicity, and emerging concerns about thromboinflammation/atherogenesis. No therapeutic meta-analysis for LL-37 was found; the only identified meta-analysis relates vitamin D and LL-37 levels as biomarkers in TB and does not establish therapeutic efficacy or safety.

Research Methodology#

We synthesized the LL-37 literature across mechanistic, methodological, and translational domains and identified convergent research gaps with concrete study needs. Below, we summarize the major limitations and priority studies, followed by an embedded table of actionable recommendations.

Major research gaps and methodological limitations

1. Resistance, tolerance, and cross-resistance risks. Despite early assumptions that host-defense peptides would not engender resistance, multiple lines of evidence indicate sub-inhibitory LL-37 can induce tolerance, mutagenesis, and phenotypic shifts, with biofilm-associated cells particularly recalcitrant; cross-resistance with other antimicrobials remains insufficiently defined. The clinical prevalence and fitness costs of LL-37 tolerance, and its implications for innate immunity, remain largely unquantified.

2. Antibiofilm mechanisms and limited efficacy against mature biofilms. The precise mechanism(s) by which LL-37 penetrates or disrupts biofilms is incompletely understood, and activity against established biofilms is often weak or absent, with outcomes varying across assays and conditions. Preventive versus disruptive effects are not systematically separated in most studies.

3. Physiological instability and matrix effects. LL-37’s activity declines in physiologic salt and acidic pH, it is susceptible to host and microbial proteases, and its effects can be inhibited by wound fluids and glycosaminoglycans; protease-resistant analogs improve stability but are under-tested in relevant matrices.

4. Assay variability and poor in vitro–in vivo correlation. Different antimicrobial assay formats yield inconsistent potency estimates, often with low replication and cross-lab variability, complicating dose-setting and translation; standard MIC-style tests overlook immunomodulatory and matrix-modified activity.

5. Production, scale-up, and cost constraints. Chemical synthesis and extraction are expensive and low-yield, while recombinant production requires optimization for industrial scale and stability, limiting robust preclinical and clinical testing.

6. Pleiotropy and context-dependent risks. LL-37 exerts dual roles across tissues and diseases, including pro- and anti-tumor effects and contributions to autoimmune/allergic pathology, creating safety uncertainties and a need for context-specific biomarkers and risk stratification.

7. PTMs, variants, and supramolecular states. Post-translational modifications (e.g., citrullination) and diverse natural/cleavage variants alter antimicrobial and immunomodulatory functions; LL-37’s conformational plasticity and fiber/oligomer formation complicate mechanism and assay interpretation.

8. Receptor targets and intracellular mechanisms. Validated host and microbial receptors and intracellular targets remain sparse, limiting rational design and prediction of off-target effects.

9. Microenvironment and microbiota interactions. LL-37 acts within AMP “cocktails” and is regulated by microbial cues; single-agent tests in simplified conditions miss synergy/antagonism and population variability.

10. PK/PD and target exposure gaps. Quantitative exposure–response relationships in tissues and biofluids are limited, hindering dose optimization and safety margins; delivery modalities remain under-developed in clinically relevant settings.

Priority studies most needed

• Evolution and resistance surveillance: Longitudinal in vitro evolution and in vivo selection studies, with genomic/transcriptomic profiling of LL-37–tolerant isolates and assessment of cross-resistance patterns; monitoring in relevant infection models.
• Mechanistic antibiofilm work: High-resolution imaging and single-cell analyses in standardized biofilm models that compare prevention versus disruption; head-to-head combination screens with antibiotics under physiologic salt/pH and biofluid-spiked conditions.
• Stability and delivery in realistic matrices: Systematic testing of LL-37 and stabilized analogs (e.g., D-/cyclized/encapsulated) in sputum, wound exudate, and serum; protease mapping and protective formulations (nanoparticles, hydrogels) with release kinetics and retained bioactivity.
• Assay standardization and reporting: Inter-laboratory ring trials establishing a validated panel spanning bactericidal, anti-biofilm, immunomodulatory, and matrix-modified assays, with minimal reporting standards and replication benchmarks.
• Scalable manufacture: Bioprocess optimization of recombinant production (host selection, secretion tags, purification), stability-formulation screening, and cost-of-goods modeling to enable animal GLP toxicology and early-phase trials.
• Safety, pleiotropy, and biomarkers: Tissue- and disease-specific mechanistic studies and conditional models to define when LL-37 is protective versus pathogenic; discovery of predictive biomarkers (e.g., protease activity, NET/AMP signatures) and monitoring plans.
• PTM/variant SAR and structure: Systematic structure–activity studies across PTMs and natural/cleavage variants with multi-endpoint readouts (antimicrobial, TLR modulation, cytotoxicity) and structural methods (NMR/cryo-EM) to link conformation to function.
• Target deconvolution: Proteomic pull-downs, CRISPR screens, and chemical biology to identify host/microbial receptors and intracellular targets; mapping signaling pathways to anticipate off-target effects.
• Microbiota-aware efficacy: Organoid and co-culture models with defined microbial communities; synergy/antagonism studies with endogenous AMPs and antibiotics; exploration of microbiota-driven regulation of LL-37.
• PK/PD and delivery optimization: Quantification of tissue/biofluid exposure and PD endpoints in relevant species; PBPK modeling; evaluation of local versus systemic delivery routes and depot formulations to achieve efficacious exposure with safety.

Together, these studies would close key gaps in mechanism, measurement, safety, and translation, enabling rational development of LL-37-based interventions and informed risk management in disease-specific contexts.

Evidence Quality Assessment#

The evidence base for LL-37 currently consists primarily of preclinical studies. On the evidence hierarchy:

• Systematic reviews/meta-analyses: Limited availability
• Randomized controlled trials (human): Not completed
• Animal studies: Extensive body of research
• In vitro studies: Multiple cell culture experiments
• Case reports: Limited anecdotal evidence

Related Reading#

• LL-37 overview and research guide
• LL-37 dosing protocols
• LL-37 molecular structure